Celgene (CELG) Wins FDA Approval for Pomalyst in Multiple Myeloma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Celgene (CELG) Affirms Approval of Pomalyst for Multiple Myeloma Patients
February 8, 2013 3:56 PM ESTCelgene Corporation (Nasdaq: CELG) announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.
Supporting the approval were the results of MM-002, a phase II,... More
Approval of Celgene's (CELG) Pomalyst Largely Expected by Street (ONXX)
February 8, 2013 6:57 AM ESTCelgene's (Nasdaq: CELG) Pomalyst (pomalidomide) might have some potential after all.
According to a recent Bloomberg survey of five analysts, Pomalyst is likely to win FDA approval for the treatment of multiple myeloma in patients who have failed at least two prior... More
